Conatus Pharmaceuticals | TalkMarkets | Page 1
No data available
No data available

People who follow this stock (52)

View All

Latest Posts

About This Stock More About This Stock
Conatus Pharmaceuticals: Should You Buy This Stock?
Article By: Quad 7 Capital
Friday, March 2, 2018 8:24 PM EDT
Conatus Pharmaceuticals was initiated with Outperform rating and $16 (208% upside) price target at Oppenheimer. The stock is absolutely flying on this news, but there are other reasons to be bullish beyond today’s action.
In this article: NVS, CNAT
Read
Conatus Pharmaceuticals Launches Small Offering For Pipeline Expansion
Article By: Terry Chrisomalis
Friday, May 12, 2017 7:05 PM EDT
The offering doesn’t seem to make sense after the Novartis (NVS) licensing deal being signed.
In this article: CNAT, NVS, RHHBY
Read
Conatus Pharmaceuticals Announces Novartis Takes Option To License Emricasan
Article By: Terry Chrisomalis
Saturday, May 6, 2017 11:36 AM EDT
With the option being exercised by Novartis this now opens Conatus to many good perks.
In this article: CNAT, NVS
Read
Biotech Review - Thursday, May 4
Video By: Jonathan Rose
Thursday, May 4, 2017 1:13 PM EDT
Stocks and review of the biotech market.
In this video: CNAT Also: IBB, XBI
Watch
Conatus Pharmaceuticals Announces Two Poster Presentations At EASL Conference
Article By: Terry Chrisomalis
Saturday, April 22, 2017 4:34 PM EDT
Conatus Pharmaceuticals shows two posters at EASL conference that show a decrease in MELD might correlate with longer-term survival in transplant patients.
In this article: CNAT Also: NVS
Read
All Posts

Latest Tweets for $CNAT

No tweets yet!

PARTNER HEADLINES